IP Library Granted Patent US 9,862,775
Granted Patent B2
US 9,862,775 · App. 14/639,679 · Granted Jan 9, 2018

Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof

Inventors: Byoung Se Kwon (Gyeonggi-do, KR); Kwang-Hui Kim (Gyeonggi-do, KR); Young-Ho Kim (Gyeonggi-do, KR); Ho-Sik Oh (Ulsan, KR); Don-Gil Lee (Gyeonggi-do, KR); Seung-Joo Lee (Goyang-si, KR); Beom-Kyu Choi (Gyeonggi-do, KR); Insoo Park (Seoul, KR); Chungyong Han (Gyeonggi-do, KR)
Assignee: Eutilex Co., Ltd.
C07K16/3061A61K47/4863A61K47/48484C07K16/2833G01N33/577G01N33/57426A61K2039/505C07K2317/24C07K2317/622C07K2317/732C07K2319/03C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,862,775
App. No.
14/639,679
Granted
Jan 9, 2018
Kind
B2
Abstract

Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated.

Claims (11)

1. A monoclonal antibody specific to B cell lymphoma, comprising:

a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4; and

a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

2. The monoclonal antibody of claim 1 , wherein the monoclonal antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.

3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is in the form of a full-length antibody or an antibody fragment.

4. The monoclonal antibody of claim 3 , wherein the antibody fragment is selected from the group consisting of single chain variable fragment (scFv), dsFv, Fab, Fab′, and F(ab′)2.

5. The monoclonal antibody of claim 1 , wherein the monoclonal antibody comprises a heavy chain constant region selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, and IgD.

6. A pharmaceutical composition comprising the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

7. A composition for diagnosing B cell lymphoma, comprising the monoclonal antibody of claim 1 .

8. An antibody-drug conjugate, in which the monoclonal antibody of claim 1 and a drug are conjugated.

9. The antibody-drug conjugate of claim 8 , wherein the drug is selected from the group consisting of a inhibitor of microtubulin structure formation, meiosis inhibitor, meiosis inhibitor, topoisomerase inhibitor, DNA intercalators, toxin, and radionuclides.

Assignments (4)
CHANGE OF ADDRESS Recorded Jul 26, 2021
From: EUTILEX CO., LTD.
To: EUTILEX CO., LTD.
Reel/Frame 057044/0548 →
NUNC PRO TUNC ASSIGNMENT Recorded Feb 9, 2017
From: NATIONAL CANCER CENTER
To: EUTILEX CO., LTD.
Reel/Frame 041215/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2016
From: PARK, INSOO; HAN, CHUNGYONG
To: NATIONAL CANCER CENTER
Reel/Frame 040775/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2015
From: KWON, BYOUNG SE; KIM, KWANG-HUI; KIM, YOUNG-HO; OH, HO-SIK; LEE, DON-GIL; LEE, SEUNG-JOO; CHOI, BEOM-KYU
To: NATIONAL CANCER CENTER
Reel/Frame 035668/0821 →
Priority Claims (1)
KR 10-2014-0026252 · Mar 5, 2014 · national
Continuity (2)
Related Publication 20160257762A1 · Sep 8, 2016
Related Publication 20170306043A9 · Oct 26, 2017